Cantor Fitzgerald Forecasts Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Kura Oncology in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings of ($2.94) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same period in the previous year, the firm earned ($0.50) EPS.

Several other equities analysts also recently weighed in on the company. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Tuesday, November 19th. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and cut their price objective for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Scotiabank dropped their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Jefferies Financial Group dropped their price target on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. Finally, HC Wainwright upped their price objective on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.38.

Kura Oncology Stock Up 6.4 %

Shares of KURA opened at $7.86 on Wednesday. The stock has a market capitalization of $611.19 million, a price-to-earnings ratio of -3.33 and a beta of 0.81. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17. The business’s 50 day simple moving average is $9.88 and its 200-day simple moving average is $16.09. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Kura Oncology during the third quarter valued at approximately $25,000. The Manufacturers Life Insurance Company raised its position in Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after acquiring an additional 1,976 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after acquiring an additional 2,076 shares in the last quarter. Hsbc Holdings PLC raised its position in Kura Oncology by 13.4% during the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after acquiring an additional 2,167 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after acquiring an additional 3,092 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.